The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Exciting updates in higher-risk MDS at ASH 2022
In this video, Valeria Santini, MD, University of Florence, Florence, Italy, highlights exciting updates in higher-risk myelodysplastic syndromes (HR-MDS), commenting on the STIMULUS-MDS1 trial (NCT03946670) and the clinical application of the Molecular International Prognostic Scoring System (IPSS-M). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
